JGOG endometrial cancer committee: JGOG2033: Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate risk endometrial carcinoma.
(JGOG-AGOG Joint Symposium “JGOG, our current studies and future plan” 2006)
A newly established human monoclonal antibody, HMOCC-1 inhibits adhesion of human ovarian carcinoma cells to mesothelial cells.
(Asian & Oceanic Congress of Obstetrics & Gynecology 2005)